To include your compound in the COVID-19 Resource Center, submit it here.

Synthetic biology play Senti emerges with $53M series A

Senti Biosciences Inc. (South San Francisco, Calif.) announced a tranched $53 million series A round led by existing investor New Enterprise

Read the full 215 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE